EU panel supports approval of 4 new drugs

04/29/2013 | Reuters

The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of Roche Holding and Curis' advanced basal cell carcinoma drug Erivedge as well as Astellas Pharma and Medivation's prostate cancer treatment Xtandi. Genzyme's MAC1, a tissue-engineered treatment for cartilage defects, and Vivus' erectile dysfunction drug Spedra also received approval recommendations from the panel.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ